C2-Incidencia

April 19, 2018 | Author: Anonymous | Category: N/A
Share Embed


Short Description

Download C2-Incidencia...

Description

Incidencia de las enfermedades hematológicas malignas en Europa por subtipos morfológicos : resultados del proyecto HAEMACARE Pr Marc Maynadié Registre des Hémopathies Malignes de Côte d’Or EA 4184 – Université de Bourgogne

Proyecto financiado por la Comunidad Europea Para aumentar la disponibilidad y la estandarización de datos de registros en Europa Iniciado dentro del programa EUROCARE IV (93 Registros europeos) HAEMACARE : 44 registros - 20 países - 2000-2002 - > 97 000 casos

5 regiones :

Norte : países nórdicos Inglaterra y Irlanda : UK Centro : Francia, Alemania, Bélgica, Holanda,.. South : España, Portugal Italia, Malta,….

Groupos de enfermedades

• Usar la ICD-O-3 para analizar los datos • Hacer grupos de enfermedades para conducir análisis de sobrevivencia a diferente nivel de detalles • Grupaje con hierarchia : estrategia usada en el consorcio INTERLYMPH (Morton L et al, Blood, 2007)

Hierarchical group ICD-O-2 codes* WHO categories

ICD-O-3 codes

Classical Hodgkin lymphoma, lymphocyte-rich 9651 Classical Hodgkin lymphoma, mixed cellularity 9652 Classical Hodgkin lymphoma, lymphocytedepleted 9653-9655 Classical Hodgkin lymphoma, nodular sclerosis 9663-9667 Classical Hodgkin lymphoma, NOS Nodular lymphocyte predominant Hodgkin lymphoma

1

2

3

4

5

HL-C

HL-CLR/MC/LD

HL-C-LR

LN HL

HL-C

HL-CLR/MC/LD

HL-C-MC -

LN HL

HL-C

HL-CLR/MC/LD

HL-C-LD -

LN HL

HL-C

HL-C-NS

-

-

LN HL

HL-C

-

-

-

LN HL

HL-NLP

-

-

-

9657, 9658 LN HL 9652

6

9653-9655

9663-9667 9650, 9661, 9662

9650, 9661, 9662 9659, 9660 9659

Morton L et al, Blood, 2007 Turner JJ et al, Blood, 2011

Linfoma de Hodgkin Crude incidence rate/100 000inh/y

by region

by age

HL NOS/classical HL, lymphocyte- rich

2

HL, lymphocyte depletion

Crude Incidence Rates x 100,000

HL, nodular sclerosis

1.5

1

0.5

0

1990

1991

1992

1993

1994

1995

Year of diagnosis

1996

1997

1998

1999

2000

2001

2002

Incidence and mortality estimates in France by Hodgkin L Scenario= C ==> Figure 3: Tendance chronologique pour la France

1980

1985

1990

1995 Année

2000

2005

2010

50.0

50.0

10.0 1.0 0.1

0.5

1.0

5.0

10.0 0.5 0.1

Incidence estimée Homme Incidence estimée Femme Mortalité estimée Mortalité observée

5.0

0.5 1.0 5.0 10.0 T aux standardisés m onde (échelle log) 0.1

10.0 5.0 1.0 0.5 0.1

T aux standardisés m onde (échelle log)

50.0

Femme

50.0

Homme

1980

1985

1990

1995 Année

2000

2005

2010

ICD-0-3 code

L de las celulas B maduras

N° de casos

Todos

Hombres

Mujeres

42 855

19.14

21.30

17.07

LLC/SLL

9670/9823

11 019

4.92

5.97

4.01

L Follicular

9690,9691, 9695,9698

4 881

2.19

2.1

2.26

L BDGC

9675, 9678, 9679, 9680, 9684

8 538

3.81

4.06

3.57

L Zona Marginal

9689, 9699, 9764

950

0.42

0.40

0.45

Enfermedades Immunoproliferativas

9671, 9760, 9761, 9762

1859

0.83

1.00

0.67

L de las c. del Manteau

9673

1012

0.45

0.64

0.27

ICD-0-3 code

L de celulas B maduras

N° de casos

All

Hombres

Mujeres

42 855

19.14

21.30

17.07

Mieloma

9732

12 192

5.44

5.85

5.06

Leucemia de Plasmocytos

9733

92

0.04

0.04

0.05

Plasmacytoma

9731, 9734

1172

0.52

0.58

0.47

Burkitt L/L

9687, 9826

488

0.22

0.31

0.13

Leucemia B

9833, 9940

652

0.29

0.46

0.13

by age

Leucemia linfoide Cronica 8

North UK 7

East Central South

Crude Incidence Rates x 100,000

6

5

4

3

2

1

0 1990

1991

1992

1993

1994

1995

1996

Year of diagnosis

1997

1998

1999

2000

2001

2002

Lymphoplasmacytic Lymphoblastic Lymphoma Burkitt

T lymphoma cutaneous

0.95

Other T cell lymphomas

0.9

Other specified NHL

0.85

Mantle cell/centrocytic

0.8

Marginal zone B cell/MALT mucose associated

0.75

Composite Hodgkin and NHL

0.7 0.65 0.6 0.55 0.5 0.45 0.4 0.35

0.3 0.25 0.2

0.15 0.1 0.05

0

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002 Year of diagnosis

Evolución de la incidencia por tipo 4 3,5 3 2,5 2 1,5 1 0,5 0 1980-1984

1985-1989

L. Lymphoplasmocytaires L. Folliculaire L. de Burkitt LNH T

1990-1994

1995-1999

2000-2005

L. du Manteau L. B diffus à grandes cellules L. de la zone marginale

Données RHEMCO 1980-2005

20 18

Crude Incidence Rates x 100,000

16 14 12

hodgkin disease non hodgkin lymphoma

10 8

6 4 2 0

1990

1991

1992

1993

1994 1995 1996 Year of diagnosis

1997

1998

1999

2000

2001

2002

Incidence and mortality estimates in France by NHL Scenario= A ==> Figure 3: Tendance chronologique pour la France

1985

1990

1995

2000

2005

2010

Année

1980-2005 : 2000-2005 :

50 5

10

50 10 5

1

1 1980

Incidence estimée Homme Incidence estimée Femme Mortalité estimée Mortalité observée

1

5 10 Taux standardisés m onde (échelle log)

10 5 1

Taux standardisés m onde (échelle log)

50

Femme

50

Homme

1980

1985

1990

1995

2000

Année

+2.7% /y in men -0.1%/y in men

+2.9%/y in women +0.4%/y in women

2005

2010

Level 1

Level 2

Level 3 recurrent genetic abnormalities

level 4 t(8;21) inv(16) t(15;17) t(9;11) t(6;9) inv(3) or t(3;3) t(1;22) mutated NPM1 mutated CEBPA

with multilineage disorders AML-MDS therapy related

Myeloid Haemopathies

Acute Myeloid Leukaemia AML NOS

Minimaly differentiated without maturation with maturation myelomonocytic monocytic/monoblastic erythoblastic megakaryoblastic basophilic A panmyelosis with myelofibrosis

myeloid sarcoma M Prol with Down Syndrome Blastic plasmacytoid dendritic cell

Myeloid leuk

AL of ambiguous lineage CML Polycythemia vera Essential Thrombocytemia Chronic idiopathic myelofibrosis

Myeloproliferative neoplasms Mastocytosis others Refractory Anaemia Refractory neutropenia Refractory thrombocytopenia RA with ring sideroblasts

Myelodysplastic syndromes

Myelodysplastic/ Myeloproliferative neoplasms Prolif with PDGFRA, PDGFRB or FGFR1

RA with excess of blasts 5q- syndrome R Cytopenia with multilin. Dysplasia Others CMML JCMML atypical CML others

Systematic mastocytosis Mast cell leukemia Mast cell sarcoma

Leucemia mieloide aguda

North UK

6

East Central South

Crude Incidence Rates x 100,000

5

4

3

2

1

0 1990

1991

1992

1993

1994

1995

1996

Year of diagnosis

1997

1998

1999

2000

2001

2002

Leucemia mieloide cronica

North UK 3

East Central

Crude Incidence Rates x 100,000

2.5

South

2

1.5

1

0.5

0 1990

1991

1992

1993

1994

1995

1996

Year of diagnosis

1997

1998

1999

2000

2001

2002

Leukemia NOS Lymphatic Leukemia NOS

Leucemias

Acute Myeloid Leukemia Chronic myeloprolipherative disorders Mature B cell Leukemia Mature cell T/NK cell Leukemia Acute (precursor cell) Lymphatic Leukemia Myelodisplastic syndrome

Crude Incidence Rates x 100,000

5

4.5

4

3.5

3

2.5

2

1.5

1

0.5

0

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

Dr Milena Sant Dr Claudia Allemani Dr Carmen Tereanu Dr Franco Berrino Istituto dei tumori Milan, Italia

Dr Roberta De Angelis Dr Roberto Capocaccia Ariana Simonetti Istituto Superiore di Sanità Roma, Italia Dr Rafael Marcos Gragera Girona, Espana

Dr Otto Visser Holanda

Dr Jean Michel Lutz Nicer, Suissa The HAEMACARE Group

Pr Marc Maynadié Dijon, Francia

View more...

Comments

Copyright © 2017 HUGEPDF Inc.